Risk-Based Thinking in Process Validation - Pharmaceutical Technology

Latest Issue

Latest Issue
PharmTech Europe

Risk-Based Thinking in Process Validation
The author describes why statistical significance would impose an unreasonable burden on manufacturers.

Pharmaceutical Technology
Volume 35, Issue 2, pp. 68-76

Fourth, the draft guidance has adopted a life-cycle approach to process validation in which the exercise is no longer considered an isolated activity, but one that is fully integrated into the development and commercial life of the product. This shift in thinking mandates a changed perspective on how validation is implemented and used in an environment in compliance with current good manufacturing practice (CGMP). The requirement for an annual review of product performance is a 21 CFR 211 expectation (7). In the author's experience, that activity was rarely linked to process validation in any meaningful way. Annual reports were largely isolated from the individual release decisions for a particular lot.

One means to address FDA's draft Stage III recommendations for continued process verification is to implement near real-time evaluation of results for commercial materials. With the increasingly available electronic tools of laboratory information-management systems, system control and data acquisition, among others, the results of testing for any lot can be rapidly compared with prior results for evidence of a shift in performance. This capability and expectation can substantially reduce the importance of the Stage II data. Although Stage II is important as part of the initial scale-up, it merely suggests future performance rather than predicting it. Release decisions in Stage III are made according to an even larger body of evidence, of which the Stage II results are only one part.

Fifth, when the 1987 process-validation guidance was issued there was an implied understanding that analytical methods should be validated. Methods and principles for that validation were not widely accepted, however, and the analysis was often labor-intensive. The ability to analyze samples in large numbers often was limited by the number of analysts available.* Process automation first appeared on the manufacturing floor, and is now found throughout the facility, including nearly all laboratories. Present-day laboratories are increasingly automated, which allows for the accommodation of larger sample sizes, higher throughput, and more timely and reliable results. Processes and products can be more effectively and expeditiously evaluated than ever before, and confidence in the results is substantially higher. As a consequence, Stage II lots can be characterized better than ever before, and added lots to build knowledge of process capability are not needed as much.

*The author has encountered numerous instances where the number of validation exercises that could be performed was limited by the laboratories' ability to analyze the validation samples in a timely manner. This was complicated by the sample numbers taken for purposes of validation that were many times the number used for routine release. These situations are far less common with today's automated analytical laboratories.

Last, and perhaps most importantly, Stage III of the validation life cycle lasts longer than any other, and the number of batches needed to make the transition from Stage 2 to Stage 3 is really not a significant factor. Maintaining a process in a validated state over its commercial life requires several supportive controls defined under CGMP regulations. The essential elements to support a product or process over its life cycle are change control (i.e., materials, procedures, test methods, and equipment), calibration, preventive maintenance, and personnel training. These mechanisms support the acceptability of the product or process for the longest period, and the number of successful Stage II batches completed is largely irrelevant.

Recommendations for Stage II

Table I: Phase II validation batch expectations.
Considering the points that this article has examined, it would be inappropriate for the author not to take a definitive stance on the number of batches that should be required. The author believes that although cogent arguments for more batches exist in some instances for complex processes, perhaps equally good reasons indicate that increasing the expected number of batches across the board would create an unnecessary (and perhaps superfluous) burden in other instances. The author believes that essentially no change in historical practices is warranted. Three batches have served industry, FDA, and the patient well for more than 20 years. The suggested approach in Table I provides a risk-based approach that gives adequate consideration to the technical, commercial, and regulatory risks. The new guidance addresses that approach by requiring that firms develop a fuller understanding of their product and process and be thus able to support its adequacy without resorting to large numbers of Stage II studies.


blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
| Weekly

What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Jim Miller Outsourcing Outlook Jim MillerCMO Industry Thins Out
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerFluorination Remains Key Challenge in API Synthesis
Marilyn E. Morris Guest EditorialMarilyn E. MorrisBolstering Graduate Education and Research Programs
Jill Wechsler Regulatory Watch Jill Wechsler Biopharma Manufacturers Respond to Ebola Crisis
Sean Milmo European Regulatory WatchSean MilmoHarmonizing Marketing Approval of Generic Drugs in Europe
FDA Reorganization to Promote Drug Quality
FDA Readies Quality Metrics Measures
New FDA Team to Spur Modern Drug Manufacturing
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Source: Pharmaceutical Technology,
Click here